| Ytd | 39.59% | |
| 1y | 12.89% |
| Open | 14.95 | Prev Close | 14.88 | Low | 14.59 | High | 15.79 | Mkt Cap | 2.37B |
| Vol | 4.74M | Avg Vol | 2.77M | EPS | -5.57 | P/E | N/A | Forward P/E | -8.09 |
| Beta | 3.31 | Short Ratio | 8.46 | Inst. Own | 97.56% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-04 | 50-d Avg | 11.09 | 200-d Avg | 11.58 | 1yr Est | 21.94 |
Biohaven Ltd. (NYSE:BHVN), a global clinical-stage biopharmaceutical company focused on the discover
Enrollment complete in pivotal Phase 2/3 study evaluating opakalim in focal epilepsy (RISE3); top-li
Biohaven Ltd. (NYSE:BHVN) shares fell Monday after Bank of America Securities (BofA) downgraded the
Biohaven (BHVN) shares fall as BofA downgrades the stock to Underperform, citing a risky profile ahe
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Mon
US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol
B of A Securities analyst Jason Gerberry downgrades Biohaven (NYSE:BHVN) from Neutral to Underper
BHV-1300 is the first MoDE extracellular protein degrader, a novel small molecule IgG1, 2 and 4 degr
BHV-1300 is the first MoDE™ extracellular protein degrader to enter a pivotal trial, pioneering a ne
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company f
Biohaven Ltd. (NYSE: BHVN) ("Biohaven") a global clinical-stage biopharmaceutical company fo
HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Neutral and m
Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discove
Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and lowers
RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and lowers t
https://www.sec.gov/Archives/edgar/data/1935979/000162828026029834/biohavens-3asr.htm
Citigroup analyst Samantha Semenkow maintains Biohaven (NYSE:BHVN) with a Buy and raises the pric
Phase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa a
TD Cowen analyst Tyler Van Buren maintains Biohaven (NYSE:BHVN) with a Buy and raises the price t
Biohaven shares rose in premarket trading after Xenon's Phase 3 epilepsy study showed strong sei
HC Wainwright & Co. analyst Douglas Tsao maintains Biohaven (NYSE:BHVN) with a Neutral and lo
RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and raises t
Biohaven (NYSE:BHVN) reported quarterly losses of $(1.21) per share which missed the analyst consens
RBC Capital analyst Leonid Timashev upgrades Biohaven (NYSE:BHVN) from Sector Perform to Outperfo
Biohaven Ltd. shares surged 3.42% in after-hours trading following an SEC filing that detailed inves
Reports positive early clinical experience from first and only clinically validated, extracellular p
Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and lowers
Biohaven shares are flat after the company announced its Phase 2 proof-of-concept study of BHV-7000
(Editor’s note: The future prices of benchmark tracking ETFs and the headline were updated in the st
Biohaven's Phase 2 study with BHV-7000 in MDD did not meet its primary endpoint of reducing depr
HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Neutral and m
US stock futures slightly lower. Stocks to watch: NVIDIA, Dynavax, Sobr Safe, Davis Commodities, Bio
Biohaven shares fell 16.19% in after-hours trading Wednesday after its Phase 2 depression drug trial
The company considers the depression subgroup analyses as hypothesis generating but based upon strat
Biohaven Ltd. (NYSE:BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company fo
HC Wainwright & Co. analyst Douglas Tsao downgrades Biohaven (NYSE:BHVN) from Buy to Neutral
UBS analyst Ashwani Verma downgrades Biohaven (NYSE:BHVN) from Buy to Neutral and lowers the pric
JP Morgan analyst Tessa Romero maintains Biohaven (NYSE:BHVN) with a Overweight and lowers the pr
Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and lowers
Citigroup analyst Samantha Semenkow maintains Biohaven (NYSE:BHVN) with a Buy and lowers the pric